Health regulators are facing calls to expedite the approval process for two dementia drugs that have shown significant promise in clinical trials. Donanemab, developed by Eli Lilly, was found to slow cognitive decline in Alzheimer’s patients by 35%, while Lecanemab, from Eisai and Biogen, reduced the rate by 27%. Health leaders believe the introduction of these drugs could transform the way Alzheimer’s is managed, making it as treatable as conditions like diabetes or asthma. Efforts are now being made to ensure regulatory decisions are made promptly, in order to prevent patients from experiencing unnecessary delays in accessing these potentially life-changing treatments.
Denial of responsibility! Swift Telecast is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – swifttelecast.com. The content will be deleted within 24 hours.